Clinical features, pathophysiology, and treatment of medication-overuse headache
Abstract
Medication-overuse headache (MOH) is a chronic headache disorder defined by the International Headache Society as a headache induced by the overuse of analgesics, triptans, or other acute headache compounds. The population-based prevalence of MOH is 0.7% to 1.7%. Most patients with MOH have migraine as their primary headache and overuse triptans or simple analgesics. The pathophysiology of MOH is still unknown. As well as psychological mechanisms such as operant conditioning, changes in endocrinological homoeostasis and neurophysiological changes have been observed in patients with MOH. Recently, a genetic susceptibility has been postulated. In most cases, treatment of MOH consists of abrupt withdrawal therapy and then initiation of an appropriate preventive drug therapy. There is no clear evidence on which method of withdrawal therapy is the most efficacious. Withdrawal symptoms can be treated with steroids; however, not all data support this concept. As MOH can severely affect the quality of life of patients, it needs to be recognised early to enable appropriate treatment to be initiated.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Medication overuse headache treatment has few evidence-based indications.
“Medication overuse headache (MOH) is a severe burden to sufferers and its treatment has few evidence-based indications.”
From Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial (2012) · cites this paper as [1]
The citation lists haven’t been fetched yet
References 138 · Cited by 233
- Authors
- Evers, S., & Marziniak, M.
- Affiliations
- University of Münster (DE)
- Corresponding author
- Evers, Stefan
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2010-04
- Volume
- 9
- Issue
- 4
- Pages
- 391-401
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W2133949006
- Cited by
- 233
- References
- 138
- Citations by year
- 2026: 8 · 2025: 7 · 2024: 6 · 2023: 6 · 2022: 13 · 2021: 18 · 2020: 7 · 2019: 11 · 2018: 13 · 2017: 10 · 2016: 14 · 2015: 21 · 2014: 31 · 2013: 22 · 2012: 21
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Migraine and Headache Studies
- Health Sciences › Medicine › Epidemiology › Traumatic Brain Injury Research
- Health Sciences › Health Professions › Complementary and Manual Therapy › Temporomandibular Joint Disorders
- Keywords
- medication overuse headache, analgesic overuse, triptan overuse, migraine, pathophysiology, operant conditioning, genetic susceptibility, withdrawal therapy, corticosteroids, prophylaxis, prevalence, quality of life
- MeSH terms
- Adolescent, Child, Chronic Disease, Humans, Substance Withdrawal Syndrome, Headache Disorders, Secondary
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review